[
  {
    "ts": null,
    "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2024 Update",
    "summary": "GMOâs 13F portfolio increased to $31.91B in Q3 2024. Click here to read more about the holdings and trades of GMO Capital Portfolio.",
    "url": "https://finnhub.io/api/news?id=1f10612cc8dd076b517497a7701346c351e530bf49e662e6f9e4366aee31e2cd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731523255,
      "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2024 Update",
      "id": 131336623,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "GMOâs 13F portfolio increased to $31.91B in Q3 2024. Click here to read more about the holdings and trades of GMO Capital Portfolio.",
      "url": "https://finnhub.io/api/news?id=1f10612cc8dd076b517497a7701346c351e530bf49e662e6f9e4366aee31e2cd"
    }
  },
  {
    "ts": null,
    "headline": "Why Johnson & Johnson, Invitation Homes And Extra Space Storage Are Winners For Passive Income",
    "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Johnson & Johnson, Invitation Homes and Extra Space Storage have rewarded shareholders for decades and recently announced ...",
    "url": "https://finnhub.io/api/news?id=6e02e96b0186d88981343fa4f624e5427afc4a5423bc23ff7896a43d332de50d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731517241,
      "headline": "Why Johnson & Johnson, Invitation Homes And Extra Space Storage Are Winners For Passive Income",
      "id": 131329975,
      "image": "https://media.zenfs.com/en/benzinga_79/8aa5ce0d26cd5650267ad26140f9cc4d",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Johnson & Johnson, Invitation Homes and Extra Space Storage have rewarded shareholders for decades and recently announced ...",
      "url": "https://finnhub.io/api/news?id=6e02e96b0186d88981343fa4f624e5427afc4a5423bc23ff7896a43d332de50d"
    }
  },
  {
    "ts": null,
    "headline": "J&J MedTech wins IDE for Ottava to greenlight trials for surgical robot",
    "summary": "J&J MedTech is aiming to disrupt a robotic surgical market dominated by Intuitive’s Da Vinci systems.",
    "url": "https://finnhub.io/api/news?id=a71f830aec8bb189d57faa02aa91f2f067768ea7e5c4e465c9ec90d2b3539004",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731517097,
      "headline": "J&J MedTech wins IDE for Ottava to greenlight trials for surgical robot",
      "id": 131328852,
      "image": "https://www.medicaldevice-network.com/wp-content/uploads/sites/23/2024/04/shutterstock_2008564148.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J MedTech is aiming to disrupt a robotic surgical market dominated by Intuitive’s Da Vinci systems.",
      "url": "https://finnhub.io/api/news?id=a71f830aec8bb189d57faa02aa91f2f067768ea7e5c4e465c9ec90d2b3539004"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock underperforms Wednesday when compared to competitors despite daily gains",
    "summary": "Johnson & Johnson stock underperforms Wednesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=d48e05333342328173c8511a49bf80fa9ef909d4dc18298027a3f7a9358fe9ec",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731515460,
      "headline": "Johnson & Johnson stock underperforms Wednesday when compared to competitors despite daily gains",
      "id": 131413910,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock underperforms Wednesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=d48e05333342328173c8511a49bf80fa9ef909d4dc18298027a3f7a9358fe9ec"
    }
  },
  {
    "ts": null,
    "headline": "Texas Instruments and Other Overlooked Dividend Aristocrat Stocks",
    "summary": "Texas Instruments and Other Overlooked Dividend Aristocrat Stocks",
    "url": "https://finnhub.io/api/news?id=7b56ae324a4dabc53add368ff7548ef7c11e2e389633fbf244180afe69ddbc14",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731496080,
      "headline": "Texas Instruments and Other Overlooked Dividend Aristocrat Stocks",
      "id": 131413911,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Texas Instruments and Other Overlooked Dividend Aristocrat Stocks",
      "url": "https://finnhub.io/api/news?id=7b56ae324a4dabc53add368ff7548ef7c11e2e389633fbf244180afe69ddbc14"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson MedTech Receives IDE Approval for OTTAVA Robotic Surgical System",
    "summary": "New Brunswick - Johnson & Johnson MedTech, a global leader in cardiovascular, orthopaedic, surgery and vision solutions, today announced that the U.S. Food & Drug Administration has approved the...",
    "url": "https://finnhub.io/api/news?id=b3e0d636fdf36d806d9bc5f7a60255c55f69f04b814aea96c1617ffe3ff8d354",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731493063,
      "headline": "Johnson & Johnson MedTech Receives IDE Approval for OTTAVA Robotic Surgical System",
      "id": 131325227,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "New Brunswick - Johnson & Johnson MedTech, a global leader in cardiovascular, orthopaedic, surgery and vision solutions, today announced that the U.S. Food & Drug Administration has approved the...",
      "url": "https://finnhub.io/api/news?id=b3e0d636fdf36d806d9bc5f7a60255c55f69f04b814aea96c1617ffe3ff8d354"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Tracking Well Above The Industry",
    "summary": "Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.",
    "url": "https://finnhub.io/api/news?id=b93cf744417e6816b73bb9510095e2913406cda0e8427554ff425e4123bc4232",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731489024,
      "headline": "Johnson & Johnson: Tracking Well Above The Industry",
      "id": 131324406,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413108793/image_1413108793.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.",
      "url": "https://finnhub.io/api/news?id=b93cf744417e6816b73bb9510095e2913406cda0e8427554ff425e4123bc4232"
    }
  },
  {
    "ts": null,
    "headline": "J&J sues federal government for halting 340B rebate plan",
    "summary": "The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug discount program, instead of offering upfront discounts.",
    "url": "https://finnhub.io/api/news?id=363d40b09149faa9d599add937315443fe778f1868f5d991f15d727f9b0bd69c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731486788,
      "headline": "J&J sues federal government for halting 340B rebate plan",
      "id": 131330671,
      "image": "https://imgproxy.divecdn.com/pr0Mvz1IGD_KlfJUly0I028GxFgiUqgZjkGgcxcIMTc/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0pKXzMzdGcycE8uanBn.webp",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug discount program, instead of offering upfront discounts.",
      "url": "https://finnhub.io/api/news?id=363d40b09149faa9d599add937315443fe778f1868f5d991f15d727f9b0bd69c"
    }
  },
  {
    "ts": null,
    "headline": "Q3 2024 Legend Biotech Corp Earnings Call",
    "summary": "Q3 2024 Legend Biotech Corp Earnings Call",
    "url": "https://finnhub.io/api/news?id=b157b7c16856683398c4d330a26ca532b34b6d54b7365f4a1d098b3744779cec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731486537,
      "headline": "Q3 2024 Legend Biotech Corp Earnings Call",
      "id": 131320341,
      "image": "",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Q3 2024 Legend Biotech Corp Earnings Call",
      "url": "https://finnhub.io/api/news?id=b157b7c16856683398c4d330a26ca532b34b6d54b7365f4a1d098b3744779cec"
    }
  },
  {
    "ts": null,
    "headline": "TRex Bio raises $84M to compete in crowded immune drug field",
    "summary": "The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune system.",
    "url": "https://finnhub.io/api/news?id=177ea697e2e1dc5f46ef27e884ed009d8ec3a86b5dd10d151539c6e93100ae97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731481200,
      "headline": "TRex Bio raises $84M to compete in crowded immune drug field",
      "id": 131325824,
      "image": "https://imgproxy.divecdn.com/YK0ND5sRtkoQ3E8WppaIm-CXH-YmLxW22mIxzInyYIU/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Kb2huc3Rvbl9Fcndpbl9DRU9fVFJleEJpb18yMDI0X2NvcHkuanBlZw==.webp",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune system.",
      "url": "https://finnhub.io/api/news?id=177ea697e2e1dc5f46ef27e884ed009d8ec3a86b5dd10d151539c6e93100ae97"
    }
  }
]